Merit Medical Systems, Inc. Q1 2026 Earnings Recap

Shares dropped 9% following Merit Medical’s Q1 report, reflecting investor disappointment with the cautious outlook and updated guidance despite solid top-line growth and margin improvement.

Key Takeaways

• Q1 revenue rose 7% GAAP and 5% constant currency to $381.9 million, driven by 2.7% organic growth plus acquisition contributions.
• Non-GAAP operating margin increased 47 basis points to a record first-quarter 19.7%.
• Non-GAAP EPS grew 9%, and free cash flow increased 26% year-over-year to $25 million.
• Guidance was updated to incorporate View Point Medical acquisition impacts, suggesting a more cautious outlook.
• Strategic initiatives included the commercial launch of the Resilience TTS Esophageal Stent and expansion of the oncology portfolio through the $140 million View Point Medical acquisition.